Vyleesi Pediatric (Under 12) Safety: What the FDA Label and Evidence Actually Say

Bremelanotide Is Not Approved for Children Under 12, Or Any Minor

The FDA-approved labeling for bremelanotide (Vyleesi) states explicitly that the drug is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Pediatric use was never studied. No weight-based dosing, no pediatric pharmacokinetic model, and no age-stratified safety data exist in any published literature for patients under 18, let alone under 12.

What the FDA Label Specifically Says

The FDA prescribing information for bremelanotide does not include a pediatric use section with approved dosing. Section 8.4 of the label notes that safety and effectiveness in pediatric patients have not been established. That single sentence carries significant regulatory weight: it means Palatin Technologies was not required to complete pediatric studies under the Pediatric Research Equity Act (PREA) because HSDD in children under 18 is not a recognized clinical entity requiring drug therapy.

Why PREA Did Not Trigger Pediatric Studies

Under PREA (codified at 21 U.S.C. § 355c), the FDA can waive the requirement to study a drug in children when the disease does not occur in that population. HSDD, as defined by the DSM-5 criteria applied in RECONNECT, requires adult sexual function as a baseline. The FDA granted a full waiver, which is why no controlled pediatric data exist and none are planned.

The RECONNECT Trial: Adult Data Only

The key evidence supporting bremelanotide's approval came from the RECONNECT program, two randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019 [1]. The combined enrollment was 1,247 premenopausal women, mean age approximately 36 years, all with a confirmed DSM-5 diagnosis of HSDD.

Primary Endpoints and What They Measured

RECONNECT measured change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. Bremelanotide 1.75 mg subcutaneously produced statistically significant improvements on both co-primary endpoints versus placebo (P<0.001 for FSDS-DAO; P<0.001 for desire domain) [1]. These endpoints have no validated pediatric analogs.

Safety Profile Observed in Adults

The most common adverse events in RECONNECT were nausea (40.0% bremelanotide vs. 1.2% placebo), flushing (20.3% vs. 0.3%), and injection-site bruising (11.0% vs. 7.1%) [1]. Transient blood pressure increases of approximately 2 to 4 mmHg systolic and 1 to 2 mmHg diastolic occurred within one hour of dosing and resolved within 12 hours. These hemodynamic effects have not been characterized in children, whose baseline cardiovascular parameters differ substantially from those of adults.

No Dose-Finding Data Exist Below Adult Weight Ranges

Bremelanotide is dosed as a fixed 1.75 mg subcutaneous injection regardless of body weight in adults. Because no pediatric pharmacokinetic studies exist, there is no basis for weight-based dosing extrapolation. For context, a 1.75 mg dose in a 20 kg child would represent approximately 87.5 mcg/kg, more than four times the per-kilogram exposure in a typical 80 kg adult woman. Systemic melanocortin agonism at that relative dose is unstudied and potentially harmful.

Melanocortin Receptor Physiology in Children: Why This Matters

Bremelanotide is a cyclic peptide melanocortin receptor agonist that binds MC1R, MC3R, MC4R, and MC5R [2]. In adults, MC4R activation in the hypothalamus modulates sexual desire circuits. In children, the same receptor is involved in energy homeostasis, puberty onset, and hypothalamic-pituitary-adrenal axis regulation.

MC4R and Puberty Signaling

MC4R variants are among the most common monogenic causes of early-onset severe obesity in children, affecting approximately 2 to 5% of severely obese pediatric patients [3]. The receptor interacts with kisspeptin and GnRH neurons that govern pubertal timing. Pharmacological agonism of MC4R in a pre-pubertal child could theoretically accelerate or disrupt gonadotropin-releasing hormone pulse patterns. No human safety data address this concern because no studies have been conducted.

MC1R and Skin Pigmentation in Growing Children

MC1R activation by bremelanotide causes dose-dependent hyperpigmentation, particularly focal darkening of the face, breasts, and gingiva [4]. The FDA label warns that this pigmentation may be permanent with repeated dosing. In adults enrolled in RECONNECT, 1% of participants discontinued because of hyperpigmentation [1]. In children with actively dividing melanocytes and greater surface-area-to-volume ratios, the risk of permanent pigmentary change may be higher, though this has not been studied.

Nausea and the Developing Brain's Chemoreceptor Trigger Zone

Nausea affects 40% of adult bremelanotide users [1]. The chemoreceptor trigger zone, where melanocortin receptors contribute to emetic signaling, is not fully mature in young children [5]. Severe vomiting in a child under 12 following accidental bremelanotide exposure could produce rapid dehydration and electrolyte disturbance.

What Happens If a Child Under 12 Is Accidentally Exposed

Accidental pediatric exposures to prescription medications kept in household settings are a documented public health concern. The American Association of Poison Control Centers logs tens of thousands of pediatric medication exposures annually [6].

Immediate Steps for Caregivers

Call Poison Control at 1-800-222-1222 the moment exposure is suspected. Do not wait for symptoms. Poison Control specialists will ask the child's age, approximate weight, and the estimated dose, have the auto-injector packaging available. For a 1.75 mg subcutaneous dose in a child under 12, the exposure is medically significant and warrants emergency evaluation.

Expected Symptom Trajectory

Based on bremelanotide's pharmacokinetics in adults, peak plasma concentration occurs approximately 1 hour after subcutaneous injection [4]. Nausea and flushing would be expected first. Blood pressure elevation, though transient in adults, could be more pronounced relative to a child's lower baseline values. Tachycardia and pallor may follow. Symptoms generally resolve within 12 hours in adults, but pediatric clearance data do not exist.

No Approved Antidote Exists

There is no specific reversal agent for bremelanotide. Management is supportive: antiemetics for nausea, blood pressure monitoring, and IV fluids if emesis causes dehydration. The FDA label does not address pediatric overdose management, which underscores why emergency medical care is essential rather than home observation.

Storage and Household Safety Recommendations

The Vyleesi auto-injector is a single-use, 1.75 mg prefilled device that resembles other auto-injector pens used for conditions like rheumatoid arthritis or multiple sclerosis. Children in households where the medication is stored may not distinguish it from a toy or a familiar medical device.

CDC and FDA Guidance on Safe Medication Storage

The FDA's Safe Use of Medicine for Older Adults guidance and the CDC's Medication Safety program both recommend locking medications away from children in childproof containers or locked cabinets [7, 8]. For bremelanotide specifically, the auto-injector should be stored at room temperature (68 to 77°F), away from light, and in a location inaccessible to anyone under 18.

Disposal Guidance

Used and unused auto-injectors should be disposed of in an FDA-approved sharps container. Community medication take-back programs, listed at DEA's disposal locator, prevent accidental access by children [8].

Hormonal and Developmental Considerations Specific to Girls Under 12

Because bremelanotide's approved indication is female sexual dysfunction, households where the medication is present are more likely to include girls. Pre-pubertal girls under 12 have distinct hormonal baselines: estradiol levels below 20 pg/mL, LH and FSH in the early follicular range, and immature hypothalamic-pituitary-gonadal (HPG) axis feedback loops [9].

Potential Interaction with the HPG Axis

MC4R neurons in the arcuate nucleus project to GnRH-secreting cells [10]. In adults, this pathway modulates libido but does not substantially alter reproductive endocrine cycling because the HPG axis is mature. In a pre-pubertal girl, agonism of the same neurons could theoretically alter GnRH pulse frequency during a sensitive developmental window. No animal reproductive toxicology data in pre-pubertal females appear in the published bremelanotide literature, and the FDA label does not address this scenario.

A Clinical Decision Framework for Pediatric Exposure Events

When a clinician in an emergency or urgent-care setting encounters a child under 12 with suspected bremelanotide exposure, three parallel tracks should run simultaneously:

1. Stabilization: establish IV access, continuous cardiac monitoring (blood pressure every 15 minutes for the first 2 hours), and baseline metabolic panel.
2. Toxicology consultation: contact regional Poison Control and document dose, route confirmation (was the auto-injector actually discharged?), and time of exposure.
3. Endocrine follow-up: arrange outpatient pediatric endocrinology evaluation at 4 to 6 weeks to assess for any pigmentary change or signs of premature pubertal activity, given the MC4R pathway concerns outlined above.

This three-track approach is not derived from any published guideline (none exist for this specific scenario) but reflects standard supportive-toxicology principles combined with bremelanotide's known receptor pharmacology.

Regulatory History and Future Pediatric Study Obligations

Bremelanotide received FDA approval on June 21, 2019 [4]. Palatin Technologies holds no open pediatric study commitments (PSCs) or post-market pediatric requirements (PMRs) for bremelanotide as of the most recent FDA action letter review. This contrasts with medications like flibanserin (Addyi), also approved for HSDD, which similarly carries no pediatric approval and no open pediatric requirements [11].

Comparison with Flibanserin in the Context of Pediatric Labeling

Both bremelanotide and flibanserin are approved exclusively for premenopausal adult women with HSDD. Neither has pediatric pharmacokinetic data. Flibanserin's label (Section 8.4) parallels bremelanotide's in stating that safety and effectiveness in pediatric patients have not been established [11]. The absence of data across both approved HSDD agents reflects the fundamental clinical reality that this condition, as currently defined, is not diagnosed in children.

Clinician Guidance: Prescribing in Households with Children

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends that clinicians counsel patients on safe storage of all hormone-active medications [12]. Bremelanotide falls within that advisory.

Counseling Points at the Time of Prescribing

When prescribing bremelanotide to a premenopausal woman in a household with children under 12, the prescriber should document the following counseling points in the clinical note:

• Storage location: locked, childproof cabinet or medication lockbox.
• Disposal plan: sharps container for used auto-injectors; take-back program for unused doses.
• Emergency contact: Poison Control number (1-800-222-1222) saved in the patient's phone.
• Recognition of accidental activation: the auto-injector fires on skin contact with the needle cap removed; teach the patient to keep the cap on until use.

When to Delay or Decline Prescribing

If a patient reports that a child in the household has a history of accessing medications or that secure storage is not feasible, the prescriber may consider whether an alternative non-pharmacological intervention for HSDD is more appropriate. The RECONNECT investigators noted that psychological and relationship factors independently predicted response, and the Society for Sex Therapy and Research recommends combined psychosexual and medical approaches [1].

What Published Literature Does and Does Not Cover

A PubMed search using the terms "bremelanotide" AND "pediatric" OR "children" returns zero results as of the date of this review. A parallel search for "melanocortin agonist" AND "pediatric safety" returns literature primarily on setmelanotide (Imcivree), a highly selective MC4R agonist approved for pediatric obesity in patients aged 6 and older [13]. Setmelanotide's pediatric safety data are not transferable to bremelanotide because bremelanotide is a non-selective melanocortin agonist with broader receptor binding.

Setmelanotide vs. Bremelanotide: Not Interchangeable Data

Setmelanotide's Phase 3 trial in Bardet-Biedl syndrome (N=44, ages 6 to 28) showed a mean weight reduction of 7.9 kg at 52 weeks [13]. That trial included patients as young as 6 years old, providing some pediatric pharmacokinetic insight into MC4R agonism. However, setmelanotide's selectivity for MC4R (Ki approximately 0.27 nM) far exceeds bremelanotide's, and bremelanotide's additional activity at MC1R, MC3R, and MC5R means adverse effects like hyperpigmentation and nausea may be proportionally greater in children. Extrapolating setmelanotide safety data to bremelanotide in a pediatric context would be clinically inappropriate.

Summary of Evidence Gaps and What Clinicians Should Know

No controlled data exist on bremelanotide in patients under 18. The FDA label provides no pediatric dosing guidance because pediatric use was waived under PREA. The drug's mechanism involves melanocortin receptors that play documented roles in pubertal development, energy regulation, and pigmentation in children. Accidental exposure in a child under 12 should be treated as a medical emergency requiring Poison Control contact and hospital evaluation.

The Poison Control hotline is 1-800-222-1222. That number applies 24 hours a day, 7 days a week, across all U.S. States and territories [6].